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[6]-Gingerol, a major phenolic compound derived from
ginger, has anti-bacterial, anti-inflammatory and anti-tumor
activities. While several molecular mechanisms have been de-
scribed to underlie its effects on cells in vitro and in vivo, the
underlying mechanisms by which [6]-gingerol exerts anti-tu-
morigenic effects are largely unknown. The purpose of this
study was to investigate the action of [6]-gingerol on two
human pancreatic cancer cell lines, HPAC expressing wild-
type (wt) p53 and BxPC-3 expressing mutated p53. We found
that [6]-gingerol inhibited the cell growth through cell cycle
arrest at G1 phase in both cell lines. Western blot analyses
indicated that [6]-gingerol decreased both Cyclin A and
Cyclin-dependent kinase (Cdk) expression. These events led to
reduction in Rb phosphorylation followed by blocking of S
phase entry. p53 expression was decreased by [6]-gingerol
treatment in both cell lines suggesting that the induction of
Cyclin-dependent kinase inhibitor, p21
cip1, was p53-indepen-
dent. [6]-Gingerol induced mostly apoptotic death in the mutant
p53-expressing cells, while no signs of early apoptosis were
detected in wild type p53-expressing cells and this was related
to the increased phosphorylation of AKT. These results suggest
that [6]-gingerol can circumvent the resistance of mutant p53-
expressing cells towards chemotherapy by inducing apoptotic
cell death while it exerts cytostatic effect on wild type p53-
expressing cells by inducing temporal growth arrest.
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INTRODUCTION
Various plant-derived compounds or phytoche-
micals are known to have ability to interfere with
carcinogenesis and tumorigenesis. There are many
evidences that many phytochemicals, such as
epigallocatechin-3-gallate (EGCG), genestine, tan-
geretin, silymarin, silibinin, and quercetin, can
inhibit the proliferation or survival of various
cancer cells and also induce cell cycle arrest.
1-5
Plant of ginger (Zingeiber officinale Roscoe,
Zingiberaceae) family is one of the most highly
consumed dietary substances in the world. In
China and Malaysia, the rhizome of ginger has
been used in traditional oriental herbal medicine
for the management of common cold, digestive dis-
orders, rheumatism, neuralgia, colic and motion-
sickness.
6 The oleoresin from rhizome of ginger
contains pungent ingredients including gingerol,
shoagol, and zingerone.
7 Recently, these phenolic
substances have been found to possess many in-
teresting pharmacological and physiological acti-
vities. Of these, [6]-gingerol (1-[4'-hydroxy-3'-
methoxyphenyl]-5-hydroxy-3-decanone), the major
pungent principle of ginger, has anti-oxidant,
anti-inflammation and anti-tumor promoting acti-
vities.
7
Anti-cancer and/or chemopreventive activities
of [6]-gingerol have been reported. For instance,
[6]-gingerol inhibited pulmonary metastasis in
mice bearing B16F10 melanoma cells through the
activation of CD8+ T cells.
8 It also inhibited tumor
promotion of ICR mice induced skin tumor by
tumor promoter (TPA),
9 and blocked the azoxy-
methane-induced intestinal carcinogenesis in
rodents.
10 [6]-Gingerol interfered with EGF-in-
duced transformation of mouse epidermal JB6 cell
line, and reduced the activation of Activator Pro-
tein-1 (AP-1), which plays a critical role in tumor
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promotion.
11 Moreover, [6]-gingerol exerted in-
hibitory effects on the cell viability and DNA
synthesis, also induced apoptosis of human
promyelocytic leukemia HL-60 cells.
12 Recently, it
has been reported that ginger root extracts and
gingerol inhibit the growth of Helicobacter pylori
CagA+ strains, which has a specific gene linked
to the development of gastric premalignant and
malignant lesions.
13 It suggests that ginger and
gingerol have effects of chemoprevention to the
gastric-intestinal cancers.
Pancreatic ductal adenocarcinoma (pancreatic
cancer) is the fifth leading cause of cancer death
in Korea. Pancreatic cancer is a fatal disease, with
a 5-year survival rate of less than 5%.
14 In the
majority of cases (> 80%), at first diagnosis,
pancreatic cancer has already become metastatic
so that conventional treatment regimens provide
minimal, if any, clinical benefit in prolonging life
or ameliorating the negative prognosis of this
disease.
15 Resistance of recurrent disease to
cytotoxic drugs is the principal factor limiting
long-term treatment success against pancreatic
cancer. The oncogenesis of pancreatic cancer in
particular appears to favor the development and
subsequent expansion of cell clones that are
resistant to apoptotic triggers. The basis for failed
apoptosis and more specifically the cause of
chemotherapy resistance in pancreatic cancer is
multifactorial. Molecular mechanisms implicated
to date include expression of P-glycoproteins and
other multidrug resistance proeins, mutations of
K-ras and p53, and high-level expression of Bcl-2
and other inhibitors of apoptosis.
16-18 Therefore, an
important research objective is the identification
of lead compounds that circumvent the resistance
mechanisms that limit the success of conventional
drugs.
Although anticancer activities of ginger extract
and constituents have been examined, the under-
lying mechanism has not been clarified yet. The
purpose of this work was to develop an under-
standing of [6]-gingerol's effects on pancreatic
cancer cells to begin to determine its therapeutic
value in preventing or treating this disease.
Therefore we examined the anticancer activities of
[6]-gingerol, and investigated its mechanism in
two different pancreatic cancer cell lines, HPAC
with wt p53 or BxPC-3 with mutant p53. [6]-
Gingerol's antiproliferative effects are associated
with changes in the expression or phosphoryla-
tion of Cyclin A, Cdks, p21 and Rb, and most
commonly, causes cell cycle arrest at the G1
phase. We found that [6]-gingerol is capable of
inducing cell death in the mutant p53-expressing
cells, while arresting mutant p53-expressing cells
at G1 phase. Thus, [6]-gingerol can circumvent
drug resistance induced by p53 mutations.
MATERIALS AND METHODS
Chemicals and cell culture
A purified preparation of [6]-gingerol (> 98.0%
pure) was purchased from Wako Pure Chemicals
(Osaka, Japan). It was dissolved in sterile DMSO
at a stock concentration of 50 mM and stored at
-20 . Human pancreatic cancer cells, BxPC-3 and
HPAC, were obtained from the American Type
Culture Collection (Manassas, VA, USA) and main-
tained in RPMI1640 and DMEM/F12 medium
respectively, containing 10% fetal bovine serum.
Both cell lines were incubated at 37 in a
humidified atmosphere with 5% CO2.
Assessment of cell viability
The viability of the cells was measured by the
MTT [3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide] (Sigma, St. Louis, MO, USA)
assay. The cells (4 × 10
3 cells/well) were seeded
into 96-well plates, after 24 hr they were treated
with various concentration of [6]-gingerol or
vehicle alone (0.1% DMSO) in serum containing
media. After incubation for indicated times, MTT
solution was added to the plate at a final con-
centration of 0.5 mg/mL. The cells were incubated
for 4 hr in dark at 37 . The resulting MTT-pro-
ducts were dissolved by DMSO and determined
by measuring the absorbance at 570 nm with
ELISA reader (Molecular Devices, Sunnyvale, CA,
USA). Each point represents the mean of tripli-
cated experiments.
Cell cycle analysis
Flow cytometry was performed as previouslyYon Jung Park, et al.
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described.
19 Briefly, cells were seeded into 100 mm
dishes, after 24 hr treatment with the indicated
concentrations of [6]-gingerol for indicated hours.
Following treatment, cells were trypsinized, and
washed twice with cold PBS (pH 7.4). The pellet
was fixed with cold ethanol (70%) for 12 hr at 4
and washed with cold PBS. Then, they were in-
cubated with RNase (200 g/mL final concentra μ -
tion) and stained with Propidium Iodide (100 g/ μ
mL final concentration) for 1 hr and analyzed by
flow cytometry. Flow cytometry was performed
on a FACSCalibur system equipped with argon-
ion laser (Becton Dickison Immunocytometry
system, San Jose, CA, USA). Percentages of cells
in each phase were calculated using Cell Modfit
software programs (Becton Dickinson).
Assessment of apoptosis
To identify cells undergoing apoptosis, Annexin
V-FITC Apoptosis Detection Kit (BD Pharmingen,
Franklin Lakes, NJ, USA) was used. Cells were
harvested at different intervals after [6]-gingerol
treatment, containing floating and adherent cells.
After washing with cold PBS (pH 7.4), the cells
were stained and analyze by the flow cytometry.
For each tube, 20,000 cells were immediately mea-
sured on a FACSCalibur flow cytometer. The
quantitative analysis was performed with Win
MDI program version 2.8 (provided by the Flow
Cytometry Core Facility, The Scripps Research
Institute, La Jolla, CA, USA).
Protein extraction and Western blot analysis
Whole cell lysates, used to determine the levels
of various proteins, were prepared by following
method. In brief, the pancreatic cancer cells were
seeded onto culture-dishes, after 24 hr incubation
with [6]-gingerol for the indicated times. The cells
were washed twice with cold PBS (pH 7.4) and
added cell lysis buffer (70 mM beta-glycerol-
phosphate (pH 7.2), 0.6 mM sodium vanadate, 2
M MgCl2, 1 mM Ethylene glycol-bis (2-aminoe-
thylether-)N,N,N',N'-tetraacetic acid (EGTA), 1
mM dithiothreitol (DTT), 0.5% Triton X-100, 0.2
mM phenylmethylsulfonyl fluoride (PMSF), 1X
Protease Inhibitor; Leupeptin, Pepstatin, Aprotinin,
and Antipain each 5 g/mL). Cell lysates were μ
then centrifuged at 13,200 rpm for 30 min at 4 .
The protein concentrations were measured by the
Bradford dye-binding protein assay, using bovine
serum albumin (Sigma) as a standard. For Western
blot analysis, protein samples (30 g) were solu μ -
bilized by boiling in sample buffer and subjected
to SDS-PAGE followed by electrotransfer onto
nitrocellulose membrane (Amersham Life Science,
Buckinghamshire, UK). Blots were blocked for 2
hr at rom temperature with 5% nonfat dry milk
and incubated at 4 overnight with the fol-
lowing antibodies: rabbit polyclonal anti-Cyclin A,
rabbit polyclonal anti-Cyclin D1, rabbit polyclonal
anti-Cyclin E, rabbit polyclonal anti-Cdk 2 and
rabbit polyclonal anti-Cdk 4 (Delta Biolabs, Camp-
bell, CA, USA), goat or rabbit polyclonal anti-pRb
(Ser 780) (BioSource, Camarillo, CA, USA), mouse
monoclonal anti-Rb, rabbit polyclonal anti-Cdk 6,
rabbit polyclonal anti-p21, mouse monoclonal
anti-p53, rabbit polyclonal anti-phosphatidylino-
sitol-3 kinase (PI3K) p85 subunit, goat polyclo α -
nal anti-ERK1, mouse monoclonal anti-pERK,
mouse monoclonal anti-phospho-c-jun-N-terminal
kinase (pJNK), goat or chicken polyclonal anti-
AKT1, rabbit polyclonal anti-pAKT1/2/3 (Ser
473), and mouse monoclonal anti-K-Ras (Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA).
The membranes were washed three times and
incubated with horseradish peroxidase-conju-
gated species-appropriate secondary antibodies
(Santa Cruz). After additional washing, they were
developed with enhanced chemiluminescence
reagents (Amersham Life Science), and exposed to
films in a dark room.
Statistical analysis
When appropriate, statistical significance was
tested using a two tailed Student's t-test; p 0.05
was considered significant. All values shown are
means with the corresponding standard error.
RESULTS
[6]-Gingerol inhibits cell growth on both BxPC-3
and HPAC cells
To determine antiproliferative effects of [6]-Pancreatic Cancer Cell Death Induced by [6]-Gingerol
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gingerol on two pancreatic cancer cells expressing
either wt (HPAC) or mutant p53 protein (BxPC-3),
we treated cells with [6]-gingerol ranging from 50
to 800 M. As shown in Fig. 1, cells treated with μ
different concentrations of [6]-gingerol for 0, 24,
72, and 120 h resulted in the growth inhibition in
a dose- and time-dependent manner. [6]-Gingerol
at the highest concentration (800 M) had similar μ
mean cytotoxicity over the 72 h of 89.4% and
91.2% on BxPC-3 and HPAC cells, respectively.
There was no significant difference in IC50 values
between BxPC-3 cells and HPAC cells (387.4 M μ
and 405.3 M at day 3, respectively, μ p < 0.006).
IC25 values were 186.1 and 146.3 M for BxPC-3 μ
and HPAC, respectively.
[6]-Gingerol induces cell cycle arrest
Although it was apparent that [6]-gingerol was
growth inhibitory to the pancreatic cancer cell
lines, the sustained effects on culture growth
raised suspicion that it might also affect the
proliferation of surviving cells. To test this pos-
sibility, we examined whether [6]-gingerol affects
cell cycle progression. BxPC-3 and HPAC cells
were treated with 400 M of [6]-gingerol (approxi μ -
mate IC50 at day3). As shown in Fig. 2, [6]-
gingerol caused BxPC-3 cells to accumulate in
G1-phase (59.2% in [6]-gingerol-treated vs. 42.3%
in control) within 24 hr at the expense of cells
mainly in S phase. Furthermore, this was associ-
ated with the induction of apoptosis as repre-
sented by the large sub-G1 peak. On the other
hand, cell cycle arrest of HPAC by [6]-Gingerol
Fig. 1. Effect of [6]-gingerol on survival of BxPC-3 and HPAC cells. [6]-Gingerol inhibited growth of both BxPC-3 and
HPAC cells in a dose-dependent manner. Cells were treated with different concentrations of [6]-gingerol. Control cells
(empty circle) were treated with vehicle alone (0.1% DMSO). Cells were harvested at day 1, 3 and day 5 and cell viability
was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described in Materials
and methods. Percent viability was calculated by comparison with controls. Values shown as the mean ± SEM obtained
from four independent experiments.
Fig. 2. [6]-Gingerol induces cell cycle arrest in both
BxPC-3 and HPAC cell lines. Exponentially growing cells
were exposed to either 0.1% DMSO (control) or [6]-
gingerol (400 M) for 24, 48 or 72 μ hrs. Cells were then
harvested, washed in PBS, and fixed in 70% ethanol.
DNA content was evaluated with propidium iodide
staining and fluorescence measured and analyzed as
described in Materials and Methods. Data are repre-
sentative of three independent experiments.Yon Jung Park, et al.
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was less dramatic in HPAC cells where cellular
accumulation in G0/G1 phase was slightly higher
in [6]-gingerol treated group (64.6%) compared to
the control (54.6%). In contrast to BxPC-3 cells, we
did not detect an increase in HPAC cells with
hypodiploid DNA content, suggesting that
apoptotic cell death was not induced. At 72 hr,
HPAC cells partially recovered from [6]-gingerol-
induced growth arrest suggesting the operation of
compensatory mechanism(s).
[6]-Gingerol caused changes in various cell cycle
related protein expressions
We examined the effect of [6]-gingerol on the
levels of G1 phase-regulatory proteins by Western
blot analyses (Fig. 3). Both BxPC-3 and HPAC
cells were treated with 400 M of [6]-gingerol and μ
harvested in every 12 hr. In BxPC-3 and HPAC
cells, expression levels of various proteins were
changed by [6]-gingerol. In BxPC-3, [6]-gingerol
induced decrease in Cyclin A, Cdk 2, Cdk 4 and
Cdk 6 expression and increase in Cyclin D1 expres-
sion. [6]-Gingerol decreased the Cyclin A and Cdk
6 expression, but not Cdk 2 and Cdk 4, in HPAC
cells. Phosphorylated Rb protein was decreased in
both BxPC-3 and HPAC cells by [6]-gingerol.
Next, we studied the difference in basal and
[6]-gingerol-induced levels of p53 and p21
cip1,
between wt and mutant p53-expressing cells. In
line with previous report,
20 the basal levels of p53
were elevated in mutant p53-expressing cells.
[6]-Gingerol reduced the p53 levels of wt, but less
significantly of mutant, p53-expressing cells (Fig.
4). Expression of p21
cip1 was increased by [6]-
gingerol in both BxPC-3 and HPAC cells. It is well
known that induction of p21
cip1 is associated with
the expression of p53.
21 The treatment of [6]-
gingerol reduced the p53 level in the both cells
implying that the overexpression of p21
cip1 by
[6]-gingerol might be caused by p53-independent
events in both cell lines.
[6]-Gingerol induces apoptosis in BxPC-3 cell
Next, we assessed potential differences between
the [6]-gingerol-induced cell death in wt and
mutant p53-expressing cells. Since mutations in
p53 often compromise the ability of cells to un-
dergo apoptosis, we analyzed the mode of cell
death involved. As can be seen in Fig. 5, early
apoptosis (Annexin-V+/propidium iodide-) could
be detected in the mutant p53-expressing BxPC-3
cells 24 hr after treatment with [6]-gingerol. The
percentage of early-apoptotic cells and late
apoptotic/necrotic cells (Annexin-V+/propidium
iodide+) continued to rise, reaching a peak at 72
hr. On the other hand, [6]-gingerol did not induce
death in wild type p53 expressing HPAC cells.
HPAC cells displayed few early apoptosis and late
apoptotic/necrotic fractions until 72 hr suggesting
Fig. 3. Western blot analyses of the cell cycle regulatory
proteins. Both BxPC-3 and HPAC were treated with 400
M of [6]-gingerol, and harvested every 12 hr, and levels μ
of Cyclins, Cdks, Rb and pRb were determined by Western
blotting. The upper band of Rb indicates phosphorylated
form. pRb antibody detects specifically on Ser-780
phophorylated Rb. Data are representative of three inde-
pendent experiments. Actin was used as a standard for
each sample.
Fig. 4. Effects of [6]-gingerol on the expression of p21
cip
and p53. Both BxPC-3 and HPAC were treated with 400
M of [6]-ingerol, and harvested every 12 hr. The levels μ
of p21
cip1, a Cyclin dependent kinase inhibitor, and p53
changed by [6]-Gingerol in BxPC-3 and HPAC cells. Three
replicate experiments were done with similar results.Pancreatic Cancer Cell Death Induced by [6]-Gingerol
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that HPAC cells are highly resistance to [6]-
gingerol induced apoptosis. This observation cor-
responds to the data of cell cycle analysis where
HPAC cells had minimal sub-G1 population upon
[6]-gingerol treatment even after 72 hr.
[6]-Gingerol affects AKT activation
Based on these findings, we sought to examine
whether [6]-gingerol-induced apoptotic cell death
was accompanied by the activation of common
pro-apoptotic signaling pathways. The difference
in [6]-gingerol response of these two cell lines
may be caused by the altered PI3K/AKT path-
ways which play important roles in cell cycle
progression and cell survival.
22 [6]-Gingerol was
found to inhibit nuclear factor kappa B (NF-kB),
AP-1, cyclooxygenase-2 (COX-2) and p38 mitogen
activated protein kinase (MAPK).
23 Thus, we ex-
amined the levels of pERK, pJNK and PI3K/AKT
pathway proteins by Western blot analysis (Fig.
6). The down regulation of pJNK and pERK
MAPK was time-dependently induced by [6]-
gingerol in both cell types. In both cell lines,
there was no change of PI3K regulatory subunit,
p85 , levels by [6]-gingerol. While [6]-gingerol α
did not change phosphorylation of AKT protein
in BxPC-3 cells, active phosphorylated AKT
(pAKT) started to appear 3 hr after incubation
and increased further up to 24 hr in [6]-gingerol-
treated HPAC cells. These results imply that
[6]-gingerol-induced apoptosis in HPAC cells
(p53 wild type) is suppressed via the PI3K/AKT
pathway.
Fig. 5. Differential mode of death induced by [6]-Gingerol in pancreatic cancer cells expressing wt versus mutant p53.
Cells were treated with 400 M of [6]-gingerol for 24, 28 and 72 hrs. Annexin-V and PI staining revealed increasing μ
percentage of Annexin-positive and PI-positive cells with increasing time of [6]-gingerol in BxPC-3 cells. On the other
hand, [6]-gingerol treatment on HPAC cells showed no changes in cell viability under the identical culture condition.
The X and Y axis represents annexin V-FITC and Propidium Iodide (PI) fluorescence respectively. Population in lower-
left part (Annexin V-FITC and PI negative) is viable, and lower-right part (Annexin V-FITC positive and PI negative)
is undergoing apoptosis. Cells observed in Annexin V-FITC and PI positive (upper-right and upper-left parts) indicates
either late stage of apoptosis or dead cells. The percentage of each part is calculated in the bottom table. The figure
is representative of three independent experiments.Yon Jung Park, et al.
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DISCUSSION
Phenolic compounds comprise one of the largest
and most ubiquitous groups of plant metabolites.
They are formed to protect the plant from photo-
synthetic stress, reactive oxygen species (ROS),
wounds, and herbivores.
24 The most commonly
contained ones in foods are flavonoids and
phenolic substances. Hence, phenolic compounds
take important parts of the human diet. In
addition, current interest is raised up by many
observations that dietary phenolic compounds
have various activities such as antioxidant, anti-
inflammation and anti-carcinogenesis.
In this present study, we first investigated the
effects of [6]-gingerol, a phenolic substance de-
rived from ginger roots, on two pancreatic cancer
cell lines. We found that [6]-gingerol inhibited the
cell growth, disrupted the cell cycle progression in
both HPac cells (wild type p53) and BXPC-3 cells
(mutant p53 protein), and also induced apoptosis
in BxPC-3 cells. Interestingly, it is noticeable that
normal cell showed highly resistance to the
cytotoxic effects of [6]-gingerol. RIE (rat intestinal
epithelial cell) showed 50 percents growth inhibi-
tion at over 900 M (data not shown) of [6]- μ
gingerol for 3 days treatment. This selectivity may
be the great advantage of [6]-gingerol for the
therapeutic or preventative use. While there were
some reports that various phenolic substances
induce cell cycle arrest in some phases,
1-5 this is
the first report that reveals on [6]-gingerol effect
upon cell cycle in cancer cell lines. Western blot
analyses indicated that [6]-gingerol decreased the
expression of Cyclin A and Cdks including Cdk2,
Cdk4, and Cdk6 in BxPC-3. Also, Cyclin A and
Cdk 6 expression levels were decreased in HPAC.
Thus, the reduction of Cyclin or Cdk expressions
results the blocking of Cyclin-Cdk complexes
formation and that lowers the level of phospho-
Rb. Since Rb proteins remain in unphosphorylated
form, E2F cannot be activated and the cells fail to
enter the S phase. Cyclin D1 might be the cause
of apoptotic cell death when overexpressed.
25,26
Alternatively, increase of Cyclin D1 in BxPC-3
cells may be a feedback response to drug-induced
cell cycle arrest.
p53 is a tumor suppressor gene encoding a
transcription factor. Its tumor-suppressive activity
involves inhibition of cell proliferation through
cell cycle arrest and/or apoptosis. Mutation in p53
occurs in more than half of human cancers.
27 Cells
harboring mutated p53 lose the ability to elicit the
enzymatic DNA repair cascade, to inhibit cell
proliferation and to induce programmed cell
death, resulting in induction of uncontrolled pro-
liferation and malignancy.
28,29 Tumors consisting
of mutant p53-expressing cells exhibit high resis-
tance to radiation and chemotherapeutic drugs.
Circumventing this abnormal resistance is a major
challenge in cancer therapy.
20,30 In the present
study, we showed that [6]-gingerol exerted its
cytotoxic activy toward cancer cells harboring
mutant p53. Based on in vitro and in vivo studies,
the Cip/Kip family including p21
Cip1 were ini-
tially thought to interfere with the activation of
G1/S phase related Cyclin/Cdk complexes. The
Cyclin-dependent kinase inhibitor p21
cip1 is a
major transcriptional target of the tumor-suppres-
sor p53.
21 BxPC-3 cells have point mutated p53
proteins and the HPAC cells have the wild type
p53 proteins. While the basal levels of p53 were
elevated in mutant p53-expressing cells as
previously reported,
20 the level of p53 is decreased
by [6]-gingerol in both cell lines. Thus, p21
cip1 in-
duction by [6]-gingerol was not necessarily depen-
Fig. 6. Western bolt analysis for MPAK and PI3K/AKT
pathways in [6]-gingerol-treated pancreatic cancer cells.
The BxPC-3 (A) and HPAC (B) were incubated with 400
M of gingerol for indicated times. Cells were lysed and μ
the cell lysates (30 g) were resolved by SDS-PAGE. AKT, μ
ERK and JNK activation was analyzed by Western blotting
with anti-phospho-AKT, anti-phosph-ERK, anti-phosph-
JNK or anti-p85-specific antibodies as indicated. Equal
protein loading was confirmed by probing the membranes
with antibodies detecting the respective unphosphorylated
proteins (ERK and AKT). Three replicate experiments
were done with similar results.Pancreatic Cancer Cell Death Induced by [6]-Gingerol
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dent on p53 wild-type status since we detected
p21 induction in mutated p53 cells.
It has been reported Ras signaling through the
Raf/MAPK pathway also elevates levels of p21
cip1
in some cell types.
31-33 However it is still unclear
whether the over-expression of p21
cip1 by [6]-
gingerol is related with Ras signaling activations.
A number of phytochemicals, including EGCG,
34
tangeretin,
3 genestein and silymarin
4 have been
shown to induce cell cycle arrest accompanied by
increased p21
cip1 expression, an important Cdk
inhibitor in G1 and S phase. [6]-Gingerol also
increased the level of p21
cip1 in both cell lines. The
overexpression of p21
cip1 facilitated cell cycle
arrest effects of [6]-gingerol. Unlike other Cyclins,
Cyclin D1 level was increased in BxPC-3. It is pro-
bably as a feedback response to G1 arrest. More
recent study, however, has altered this view and
revealed that even p21
cip1 proteins are specific
inhibitors of Cyclin E- and A-dependent Cdk2,
they act as positive regulators of Cyclin D-depen-
dent kinases.
31 Thus, the increase of Cyclin D1
level in BxPC-3 cells may be the consequence of
the overexpression of p21
cip1. However, it is un-
clear why there was no change of Cyclin D1 level
in spite of G1 phase arrest and overexpression of
p21
cip1 in HPAC cells. The fact that [6]-gingerol
has different effects on the cell cycle in different
cell lines is intriguing and suggests that the ability
of [6]-gingerol to affect the cell cycle may be
dependent on other genetic alterations that the
tumor harbors. For example, the levels of Cyclins,
Cyclin-dependent kinases, their inhibitors, or the
status of tumor suppressor genes such as p53 and
Rb, that are all involved in cell cycle regulation,
may determine whether a chemical inhibitor
(drug) results in cell cycle arrest or not.
Exposure of mammalian cells to growth factors
or genotoxic stress elicits a variety of cellular
responses, including the activation of protein
kinase cascades involving ERKs, stress-activated
protein kinases (SAPK/JNK) and p38 MAPK.
35
Therefore, we determined the effect of [6]-gingerol
on the activation of extracellular signal-regulatted
protein kinase-1/2 (ERK1/2), p38 MAPK, and
JNK, which are representative MAPKs involved in
a wide array of cellular signaling cascade. PI3K/
AKT pathway has an important role in preventing
cells from undergoing apoptosis and contributing
to the pathogenesis of malignancy.
36 More re-
cently evidences have suggested that this pathway
is also associated with the regulation of cell cycle
progression.
22 The anti-cancer activities of [6]
gingerol could be associated with a control of
signal transduction of PI3K/AKT pathway and
this led us to investigate the change of the
survival pathway-associated proteins. In the both
cells [6]-gingerol could not affect the expression of
the regulatory subunit of PI3K, p85 . However, α
[6]-gingerol increased phosphorylation of AKT,
which is regulated by PI3K, in only the HPAC
cells. Activated AKT is known to promote the cell
survival by anti-apoptoic mechanism.
37 Additio-
nally, activated AKT also phosphorylates and
inactivates the proapoptotic protein, BAD.
22,36,38 In
HPAC cells, the increase of phospholated AKT
might protect apoptosis, despite of cell cycle arrest
by [6]-gingerol. On the other hand, there was no
change in phosphorylation of AKT by [6]-gingerol-
treated BxPC-3 cells and thus failed to counteract
the gingerol-induced apoptotic cell death.
In conclusion, we describe experiments that
show [6]-gingerol induces apoptotic cell death in
p53-mutant cancer cells. The death mechanism
was characterized, revealing that [6]-gingerol not
only initiated cell cycle arrest but ultimately
caused cell death through apoptosis. Thus, [6]-
gingerol, is capable of killing cancer cells ex-
pressing mutant p53, overcoming the phenotypic
resistance to chemotherapy- and irradiation-in-
duced cell death. These findings support the
importance of studying [6]-gingerol and gingerol-
related compounds as anticancer agents that can
potentially eradicate tumors resistant to radiation
and to currently available chemotherapy.
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